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C
ardiovascular disease (CVD) is a leading cause of death in
the world today. The need for a precise and repeatable
method foraccuratelymeasuringandquantifyingthelipoprotein
density proﬁle for studies dealing with CVD is necessary for
screening, prediction of disease, and possibly monitoring the
eﬀectiveness of treatment.
15 Several years ago, recognizing the
contribution that modern methods of analytical chemistry can
contribute to supporting medical research and new healthcare
initiatives,weformeda“laboratoryforcardiovascularchemistry”.
We selected capillary electrophoresis,
68 density gradient ultra-
centrifugation (DGU),
912 and mass spectrometry,
1315 as the
most information-rich methods and amenable to clinical studies.
OurresearchhasshownthatDGUhasthepotentialforproviding
high precision lipoprotein density proﬁles by reducing error in
themeasurementsthroughanunderstandingofhowDGUworks
systematically and in theory and identifying the areas for which
improvements are necessary. This method will be applied to
clinicalstudiesintheareaofriskassessmentforCVDusinglinear
discrimination analysis (LDA).
16
Density gradient ultracentrifugation has long been the gold
standard for separation, identiﬁcation, and quantiﬁcation of
lipoproteins.
1719 Ultracentrifugal methods separate lipopro-
teins based on their hydrated densities. The diﬀerent forms of
this technique include rate zonal ultracentrifugation and isopyc-
nic separations.
20,21 Each of these techniques has speciﬁc ad-
vantages and disadvantages including the accuracy of the
separation, use in fraction preparation, and the extent of skill
needed to perform these techniques. The need for a rapid and
straightforward method of lipoprotein density proﬁling that
provides the most precise information possible is therefore
necessary if lipoprotein density proﬁles are to be used in clinical
studies. Currently, the commercialized method of lipoprotein
separationthroughdensitygradientultracentrifugationisvertical
auto proﬁling (VAP) run by Atherotech. This method involves
the use of potassium bromide (KBr) as the salt present in the
aqueous gradient.
22,23 Use of this high ionic strength solution is
problematic as it has been shown to create multicomponent
aggregates of the low-density lipoproteins.
24 VAP results have been
applied to CVD risk assessment; however, the results can vary, and
the precision for an individual patient is questionable.
25
Because of the inherent labor-intensive features in density-
based lipoprotein separations methods, alternate methods for
lipoprotein characterization have been developed. Nuclear mag-
netic resonance (NMR),
2628 chromatographic,
29,30 and elec-
trophoresis-based methods
7,31,32 have been explored in order to
characterizelipoproteinsubclasses.Inthesemethods,itisnotthe
hydrateddensitythatisthedeﬁningparameterbutratherthesize
of the lipoprotein particle or mobility inside the medium. The
NMR lipoprotein proﬁling method is currently the most widely
used in clinical applications and is able to deconvolute the
lipoprotein distribution into 11 subclasses.
26 Risk assessment
analysis using NMR has shown potential for the application of
particle number instead of a cholesterol measurement for CVD
prediction. Thisapplication hasnotshown any marked improve-
ment over the standard methods currently in use.
33,34 Electro-
phoretic methods of lipoprotein separation include gel electro-
phoresis using agarose and analytical capillary isotachopheresis
(ITP),
31yetdespitethecontinuingdevelopmentandreﬁnement
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ABSTRACT: Early detection of the beginning stage of cardiovascular
disease (CVD) is an approach to prevention because the process is
reversible at this stage. Consequently, several methods for screening for
CVD have been introduced in recent years incorporating diﬀerent
analytical methods for characterizing the population of blood-borne
lipoprotein subclasses. The gold standard method for lipoprotein
subclassiﬁcation is based on lipoprotein density measured by sedimen-
tation equilibrium using the ultracentrifuge. However, this method has
not been adopted for clinical studies because of diﬃculties in achieving
the precision required for distinguishing individuals with and without CVD particularly when statistical classiﬁcation methods are
used. The objective of this study was to identify and improve the major factors that inﬂuence the precision of measurement of
lipoprotein density proﬁle by sedimentation equilibrium analysis and labeling with a ﬂuorescent probe. The study has two phases,
each contributing to precision. The ﬁrst phase focuses on the ultracentrifugation-related variables, and the second phase addresses
thosefactorsinvolvedinconvertingtheﬂuorescentlipoproteindensityproﬁletoadigitalformatcompatiblewithstatisticalanalysis.
The overall improvement in precision was on the order of a factor of 5, suﬃcient to be eﬀectively applied to ongoing classiﬁcation
studies relating to CVD risk assessment.8525 dx.doi.org/10.1021/ac2018124 |Anal. Chem. 2011, 83, 8524–8530
Analytical Chemistry ARTICLE
of these techniques, recent review articles have identiﬁed pro-
blems in inter-relating the use of these methods for identifying
individuals who have treatable early stage CVD.
35 Recently, a
nomenclature for the lipoprotein subclasses has been proposed
which we have adopted for our study.
36 This proposal is an
important step toward unifying the lipoprotein classiﬁcation
system for the diﬀerent methods that are being used.
The introduction of these analytical chemical screening meth-
ods into the clinical arena coupled with the vigorous interest and
desire of the medical community to have a reliable and accurate
method for screening for CVD has given us the motivation to
determine to what extent the DGU method for lipoprotein
characterization can be reﬁned to provide a protocol that meets
the requirements for lipoprotein testing to be used in the risk
assessment of patients (CVD/no CVD).
33 Current research by
ourgrouphasintroducedtheviabilityoftheuseofEDTAsaltsto
control the density gradient formation process under ultracen-
trifugation conditions.
1012 In particular, use of the NaBiEDTA
complex has been shown to generate a density gradient for
proﬁling the full density distribution of lipoproteins in 6 h rather
than the 48 h required for rate zonal ultracentrifugation.
11
Coupling the lipoprotein density distribution separation with
use of NBD C6-ceramide in order to image the intensity of the
subclasses can give in principle a precise measurement of a
subject’s lipoprotein density proﬁle if the precision of the mea-
surement can be improved.
12 These EDTA salt solutions have a
low ionic strength. This reduces the risk of aggregation in the low
density lipoproteins mentioned previously. However, there is
some evidence that apolipoprotein A-1 (apo A-1) loss in the high
density lipoproteins could be aﬀected by the low ionic strength.
37
The objective of the study described here was to optimize the
resolution and precision of the measurement of the lipoprotein
densityproﬁleusingtheaqueousEDTAsaltsolutionNaBiEDTA.
Factors were divided into two stages. The ﬁrst stage
addresses those factors associated with the ultracentrifugation
phase including spatial distribution of the density proﬁle, a
precise measurement of the density proﬁle, the inherent density
resolution, spin time, and temperature eﬀects. The second stage
is the imaging protocol where the ﬂuorescently labeled density
proﬁle is converted into a digital format. Factors that were
studied included the inﬂuence of the meniscus on the density
proﬁle, the stability of the density proﬁle in the postspin time
domain, contributionfrom light sourcestability,and inﬂuence of
tube orientation in the imaging measurement relative to spin
orientation. Through these enhancements, the goal was to
developahighprecisionmethodforlipoproteindensityproﬁling
that will determine whether the density distribution of a lipo-
protein particle is a viable signature for the development of
cardiovascular disease. The results obtained for the optimization
studies and the ﬁnal optimized method are reported here.
’EXPERIMENTAL SECTION
Materials. NBD C6-ceramide (6-((N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)hexanoyl)sphingosine, catalog # N1154) and
fluorospheres (0.1 μm carboxylate modified red fluorescent micro-
spheres, catalog # F-8801) were purchased from Invitrogen,
Carlsbad,CA.Sodium bismuth EDTA (C10H12N2O8NaBi34H2O)
waspurchasedfromTCIAmerica(Portland,Oregon).Dimethyl
sulfoxide (DMSO) and hexane (>95%) were purchased from
EMScience(Darmstadt,Germany).Deionizedwaterusedin
all experiments was from a Milli-Q water purification system
(Millipore, Bedford, MA). Polycarbonate thick wall ultracentri-
fugation tubes (1.5 mL, 34 mm length, catalog # 343778) were
purchased from Beckman-Coulter (Palo Alto, CA).
Serum Collection. The serum used for these studies was
acquired from a multiple donors with informed consent. The
serumwascollectedina9.5mLVacutainer treated withpolymer
gel and silica activator (366510, Beckton Dickinson Systems,
FranklinLakes,NJ).Theserumwasseparatedfromtheredblood
cells by centrifugation at 3200 rpm for 30 min at 5 C and then
stored at 86 C prior to use.
Ultracentrifugation. Ultracentrifugation was carried out using
anOptimaTLXultracentrifugeandaTLA120.2fixed-anglerotor
(Beckman-Coulter, Palo Alto, CA). Samples were spun using a
rotorspeedof120000rpm.FortheTLA120.2rotor,thesespeeds
correspond to average relative centrifugal force of 511000g.A
0.1800 M solution of NaBiEDTA was selected as the initial
concentration to achieve the desired density gradient profile.
Density Gradient Measurement. The density gradient dis-
tribution for the 0.1800 M NaBiEDTA was measured for several
different spin times ranging from 2 to 8 h. The method used
follows a procedure and calibration method developed by
Johnson et al. where 10 aliquots (20 μL volumes) are withdrawn
from well-defined positions within the gradient and their den-
sities are measured by refractive index.
11 Gradient curves were
then calculated by mapping the tube coordinate versus density
using Origin 7.0.
Fluorescent Labeling of Serum Samples. Serum samples
were stained for imaging as follows: 6 μL of serum was mixed
with 10 μLo fN B DC 6-ceramide (1 mg/mL in DMSO) and
diluted to 1300 μL using an aqueous solution of the density-
forming solute (NaBiEDTA) followed by incubation for 30 min
to achieve saturation.
11,12
Fluorescence Imaging. Fluorescence imaging was used in
monitoring the dynamics of the density gradient formation as
wellasthemeasurementofthesedimentationequilibriumdensity
profile. An image of the tube containing the fluorophore was
obtainedandanalyzedusingadigitalOptronicsMicrofireCamera
(S99808, Goleta, CA) with a Fiber-Lite MH-100 Illuminator, a
metalhalidelamp,asalightsource(MH100A,EdmundIndustrial
Optics, Barrington, NJ). A digital color microscope camera
(S99808, Optronics, Goleta, CA) was used to record the image.
The camera and light source were placed orthogonally to each
other on an optical bench to illuminate the ultracentrifuge tube
mounted in a custom-designed holder. Two filters matching the
excitation and emission characteristics of the fluorophore were
chosen. Specific settings for the Microfire camera software were a
gain of 1.000 and a target intensity of 30% to illuminate the tube.
The exposure time was optimized for sensitivity and to achieve
linearity.
The image of the polycarbonate ultracentrifuge tube was then
converted to a density proﬁle following the method described by
Johnsonetal.
11Brieﬂy,thetwo-dimensionalpixelﬁeldgenerated
by the camera software was converted to a digital matrix of
intensityversustubecoordinate(633mmlength)usingOrigin
7.0 software to generate a graphical representationof the density
proﬁle.
Polar vs Nonpolar Layering. In preliminary studies, we
determined that the meniscus of the solution was interfering
with the imaging of the lowest density lipoproteins. Following
the UC spin, samples were layered with different liquids in order
tofurtherseparatelipidsorremovethemeniscusfromtheimage.
Initial layering of the samples was done with 150 μLo fD IH 2O8526 dx.doi.org/10.1021/ac2018124 |Anal. Chem. 2011, 83, 8524–8530
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layered using gel loading tips (Sigma Aldrich, St. Louis, MO,
catalog # CLS4853). Enhanced methods of layering use 240 μL
of hexane with gel loading tips (Sigma Aldrich, St. Louis, MO).
Liquid volumes were slowly added on top of the sample without
perturbing the density profile that was generated in the UC.
Accuracy and Precision of Density Profile Measurement
Using Nanospheres.Using the fluorospheres and following the
method for density gradient measurements, the accuracy and
precision of the density measurement were studied. Briefly, 1 μL
of the fluorosphere solution was mixed with 1299 μL of 0.18 M
NaBiEDTA. A volume of 1150 μL of this mixture was then spun
as described above and imaged using a green excitation filter
(VG-6)witha bandwidthcentered at520nmanda redemission
filter (R-60) with a low cutoff at 600 nm (Edmund Industrial
Optics, Barrington, NJ).
Lipoprotein Profiling. Following the UC spin and layering,
animageofthetubewasobtainedandanalyzedusingthemethod
forfluorescenceimaging.Twofiltersmatchingtheexcitationand
emission characteristics of NBD C6-ceramide from Schott Glass
(Elmsford, NY) were chosen. A blue-violet filter (BG-12) with a
bandwidth centered at 455 nm and a yellow emission filter
(OG-515)withabandwidthcenteredat570nmwereusedasthe
excitation and emission filters, respectively. Specific settings for
the Microfire camera software were an exposure of 53.3 mS with
againof1.000andatargetintensityof30%toilluminatethetube
prior to image capture.
Effect of Spin Temperature on Density Profiles. The effect
of the temperature in the ultracentrifuge chamber on the lipid
profiles was studied when the samples were run using the prede-
scribed method and varying the temperature at which the samples
are run. Specifically, the samples are run at 278, 288, and 298 K.
Stability of Lipoprotein Profile after UC Spin. Stability of
the lipoprotein profile was studied by taking an initial measure-
ment as described previously and then recording consecutive
measurements every 30 min for a period of up to 90 min.
Precision of the Lipoprotein Density Profile Measure-
ment. Using serum from the single donor, ten replicate mea-
surements were made of the lipoprotein density profile. The ten
profiles were overlaid to identify any systematic error in the
measurement. A more quantitative and informative approach to
measuring the inherent precision of the method was introduced
that involves determining the integrated fluorescence intensities
of the 11 subclasses based on density ranges as described in the
literature.
38 For each of the subclasses, the mean value and
standard deviation of the intensitiesof each of the subclasses was
evaluated. While this analysis gives an overall estimate of the
precision of the measurement related to sample preparation, an
additional contribution of error comes from day-to-day varia-
bility in the intensity of the light source. Consequently, we
established two methods for measuring precision. The first
method (referred to as Mode 1) determines the mean value
and standard deviation of the absolutefluorescence intensities of
each of the subclasses. The second method (Mode 2) is a
normalization of data where the fluorescence intensity of each
of the subclasses is given as a percent of the total integrated
intensity. This approach eliminates the day-to-day variability of
the light source intensity.
’RESULTS AND DISCUSSION
The long-term objective of this research is to use the EDTA
gradients previously studied by our group to develop a high
precision method for proﬁling a patient’s serum using density
gradient ultracentrifugation (DGU) that could be applied to
clinical studies. On the basis of the previous work with EDTA
gradient by Johnson et al.,
11 NaBiEDTA was chosen as the
desired salt for manipulation of the density gradient formation
because of the ability to create a gradient encompasses the
density range of the lipoproteins with optimal resolution.
11
The developmental plan was divided into two stages. The ﬁrst
stageincludesallfactorsinherenttotheultracentrifugationofthe
samplestoseparatethelipoproteinsbydensity.Thesecondstage
focusesonfactorsinherenttotheimaginganddataanalysisofthe
lipoprotein density proﬁle. The overall objective of the develop-
mental work was to convert the lipoprotein density distribution
to a set of ﬂuorescence intensities for the lipoprotein subclasses
with high precision suitable for accurate classiﬁcation analysis.
Density Gradient Formation. Understanding the formation
mechanics of the density gradient allowed for the mapping of a
lipoprotein profile based on density as well as a determination of
theinherentresolutionofthedensityprofile.Theoverallprecision
of the density profile measurement is dependent on the precision
of the density gradient that is formed. We chose to use the
establishment of the sedimentation equilibrium condition as the
criterion.Thisconditionisidentifiedbytheexponentialincreasein
solution density along the ultracentrifuge tube axis. In this study,
Figure 1. Density curve progression. (A) density curve at 2 h spin time; (B) density curve at 6 h spin time.8527 dx.doi.org/10.1021/ac2018124 |Anal. Chem. 2011, 83, 8524–8530
Analytical Chemistry ARTICLE
we determined how long it takes for the solution to achieve
sedimentation equilibrium. The initial state was a homogeneous
solutionof0.1800molarNaBiEDTA.Figure1Ashowsthedensity
profileaftera2hspinat278K.Superimposedonthatprofileisthe
best fit to an exponential curve showing a systematic deviation in
the low density region (1.041.06 g/mL) and an overall data
correlationR
2valueof0.955.Theevolutionoftheprofilewasthen
extendedoveraperiodof48hspintime.At6h,(Figure1B),the
curvehasabetterfittoanexponentialfunctionwithanR
2valueof
0.9897.ThereislittlechangeinthegradientandR
2ifthespintime
is extended past 6 h. From this study, we established 6 h as the
standard spin time for our studies and used the equation derived
from this profile to convert tube coordinate to a density coordi-
nate. This is an important finding because it means that the
attainment of sedimentation equilibrium is much faster than
previously used density-forming solutes. We attribute this im-
provement to the properties of NaBiEDTA, a compact high
molecular weight structure with low viscosity which translates to
more rapid sedimentation and diffusion kinetics.
Optimization of the Spatial Separation and Precision of
the Lipoprotein Density Profile. The initial method described
previously by Johnson et al. used a 1000 μL, 0.2000 M NaBi-
EDTAaqueoussolutiontoformthegradientanddeionizedwater
(DI H2O) as a layering medium for separation of the chylomic-
rometers and TRLs that are less dense than 1.00 g/mL from the
denserVLDLandTRLs.
11Threefactorswerestudiedtoimprove
the overall spatial separation and improvement of precision. The
spatial separation was first expanded by increasing the volume of
the solutionin the ultracentrifuge tube from 1000 to1150 μL. In
addition, the concentration of the NaBiEDTA was decreased
from 0.2000 to 0.1800 M. An analysis of the precision of the
fluorescenceintensitiesofthelipoproteinsubclassesshowedthat
the precision of the low density subclasses was considerably
lower. We postulated that the use of water layering to separate
themeniscusfromthelowdensityfractionswasthesourceofthe
problem.Inthelayeringstep,thewatercanmixwiththeaqueous
gradient by convection depending upon the speed of layering
which then perturbs the position of the low density subclasses in
theultracentrifugetube.Thereisalsoanaddedfactorduetolight
scattering from the meniscus at the wavelength for NBD emis-
sion from the LDL and HDL subclasses. To resolve these
problems, we incorporated a nonpolar layering medium that is
less dense than the lipoproteins. For this purpose, hexane was
chosen as a layering medium. The volume of hexane was chosen
in order to shift the meniscus away from the imaging region.
Previousliteraturehasdocumentedthedelipidatingeﬀectthat
hexane can have on lipoproteins. These methods include long
incubation times of 30 min at high temperatures of 60 C.
39 The
layeringmethod applied here limitsthe interaction of thehexane
and lipoproteins in that the hexane only interacts with the TRL
portion of the lipoprotein proﬁle due to the density separation
and the time of interaction is minimal. Once a sample has been
layered, it is immediately imaged. The polar nature of the
aqueous gradient versus the nonpolar nature of the hexane will
also limit the hexane’s interaction with the lipoproteins. This
limited interaction means that there will be little to no eﬀect on
the lipoprotein proﬁle in the time needed to image.
Figure 2 shows the overlaid lipoproteinproﬁles for comparison
oftheinﬂuenceofchangesinthesolutionvolumeandNaBiEDTA
concentration as well as the two layering methods. The peak at
6 mm for the water-layered proﬁle is mainly the scattered light
fromthemeniscus.Forthehexane-layeredproﬁle,themeniscusis
shifted outside of the imaging ﬁeld. In addition, the convection
problem associated with water layering is eliminated by hexane
layering which does not penetrate into the aqueous phase. The
mostsigniﬁcantimprovementintheshapeofthedensityproﬁle is
inthe TRL/LDL region where theTRL forms a sharp peak at the
hexane/aqueous solution interface (8 mm tube coordinate) and
the LDL region between 9 and 18 mm where the precision of the
ﬂuorescence intensities is markedly improved. The shift in tube
coordinate for the LDL to a lower value is due to a change in the
density proﬁle as a result of increasing the volume of solution and
decreasing theinitial concentration of NaBiEDTA. The HDL and
protein distributions have not been aﬀected by these changes
because they are far removed from the meniscus region.
The change seen in the protein peak of the lipoprotein proﬁle
is of no consequence to this study due to the nature of the
imaging method and the shape of the UC tube. Since the UC
tube is curved at the bottom, the excitation over the area is not
equal,andtherefore,theimagingandquantiﬁcationofthisareais
notprecise.ItisalsoimportanttonotethattheNBDﬂuorophore
only ﬂuoresces in a nonpolar environment. Any free proteins in
this area would not cause for ﬂuorescence. The ﬂuorescence in
this area can be attributed to the high concentration of human
serum albumin (HSA)/lipid aggregates present.
Spin Temperature Effect on Density Profiles. Two tem-
perature-dependent factors are relevant to this study. The most
significantrelatestothestructuralstabilityofthelipoproteinparticles
in the sedimentation equilibrium process. A lower spin temperature
promotes thermal stability. Lipoprotein density profiles were re-
corded at 278, 288, and 298 K using serum from the single donor.
(Hexane layering was employed for imaging.) While the general
forms of the density profiles were essentially the same, there was a
clearly detectible shift in the density profiles toward the higher
densityregion.Weattributethisshifttothetemperaturedependence
of the sedimentation equilibrium constant. In the sedimentation
equilibrium equation, temperature is inversely proportional to
the slope of the density gradient.
40,41 Conceptually, at the lower
temperature, the diffusion rate is reduced while the sedimentation
rate is not influenced by the lower temperature. The influence of
temperatureontheoverallprecisionofthefluorescenceintensitywas
significant,afactorof2higherat278Kthanat298K.Onthebasisof
thesefindings,weestablished278Kasthestandardspintemperature
for the high performance lipoprotein density measurement.
Stability of the Lipoprotein Profile after UC Spin. The
stabilityof thelipoprotein densityprofileafterthespin iscompleted
Figure 2. Comparison of layering methods in lipoprotein density
proﬁles.8528 dx.doi.org/10.1021/ac2018124 |Anal. Chem. 2011, 83, 8524–8530
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isanissuethathasaninfluenceontheprecisionofthemeasurement.
Astudywascarriedoutwherethetimelapsebetweentheendofthe
spin and imaging varied from 1 to 90 min. Figure 3 shows how the
profilechangesovertimeafterasampleisspun,layered,andimaged.
The profiles in Figure 3 have used the density curve mapped in
Figure1toextrapolatethedensityrelativetotubecoordinateonthe
x-axis instead of the use of the tube coordinate scale. The figure
shows that it is the high density range of the profile that is most
affected by the time after spin. The protein peak separated at the
high density section of the lipoprotein profile begins to merge with
the HDL3 region after 30 min. The remainder of the lipoprotein
profile is remarkably stable, even after 90 min. The high density
component of the profile is most likely due to the density gradient
starting to diffuse back to the original concentration of the aqueous
solution before the UC spin. Thus, the merging peaks seen in the
HDL and protein region are due to the remixing of the HDL and
HSA into a heterogeneous solution. For repeatability and quality of
thelipoproteinprofile,theimagesarerecordedwithinafewminutes
after the UC spin is completed.
Study of the Density Resolution in DGU Using a Nano-
particle Surrogate. The class of lipoproteins covers a range of
particle sizes as well as density. We selected a commercially
available fluorescent nanoparticle (FluoSphere) as a model for a
lipoprotein particle and to study the accuracy of the density
measurement. It has a diameter of 100 nm and a density of 1.05
g/mL,closetotheaveragepropertiesofanLDLparticle.Figure4
shows the density distributions of this particle after a 6 h spin in
comparison to a standard lipoprotein density profile. Using the
density calibration equation for the 6 h spin, we determined that
the lower limit of the density resolution (ΔF/F  100) was
0.13% at 6 h. The reported density of the FluoSpheres is 1.05 g/
mL.ThedensityoftheFluoSphereswascalculatedtobe1.052g/
mL. The error of the density measurement was calculated at
0.19%. The percent relative standard deviations (%RSD) of the
densitymeasurementranged from0.01 to0.04% withanaverage
of 0.027%. This accuracy and resolution shown in measuring the
nanoparticle standard is also a measure of the inherent accuracy
and resolution of the lipoprotein density profile.
Precision of the Lipoprotein Density Profile Measure-
ment. The rationale for optimizing the precision of the lipopro-
tein density profile is based on the premise that a more accurate
classification of individuals with and without coronary artery
disease could be achieved. The platform for our developmental
workwastheinitialmethodpioneeredbyJohnsonetal.,wherethe
average %RSD was found to be 23.39%. Applying the enhance-
ments described in this study to create the high performance
lipoprotein density profiling method (HPLDP), the average %
Figure 3. Stability of the lipoprotein density proﬁle over time. Lipo-
protein density proﬁles are staggered based on the amount of time after
the UC spin that the image was taken.
Figure4. Sixhourspinproﬁlesforserumandﬂuorescentnanoparticles.
Figure 5. Repeatability of lipoprotein density proﬁle.
Figure6. HPLDPlipoproteinsubclasserrorfortotalintensity(Mode1).8529 dx.doi.org/10.1021/ac2018124 |Anal. Chem. 2011, 83, 8524–8530
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RSD was reduced to 4.42%. The method used to determine the
precision of the subclass measurements is summarized in the
Experimental Section. The strategy was to obtain 10 replicate
measurements of the density profile. Figure 5 shows all 10
lipoprotein density profiles overlaid from one of the volunteer’s
serum samples. Again, the x-axis density scale was extrapolated
fromtheequationfoundinFigure1.Thereareveryfewdifferences
that can be distinguished between profiles. The next step was to
extract from the profiles the fluorescence intensities of each of the
subclasses. From this data, the mean value and %RSD for each
subclass was calculated. The results are presented in histogram
formshowninFigure6alongwitherrorbarsforeachsubclass.The
errors of the TRL and low density LDL regions of the profile are
the most significantly reduced. This effect can be related to the
change in layering methods. The polarnonpolar relationship of
the aqueous gradient to the hexane prevents diffusion of the
layering medium and therefore reduces the error of the profile.
The reduction of error in this method fits the guidelines estab-
lished by the National Cholesterol Education Program that
measurement of lipoproteins must meet a total error of less than
12%.
42 The error of the system was tested for multiple serum
samples. The relative error for the different profiles was similar to
the sample presented here with an average %RSD between
samples of 5.28% ( 0.88. This shows that the error between
lipoprotein profiles is due to the method and not sample bias.
Normalization of the Lipoprotein Density Profile. An
additional class of factors influencing precision is linked to the
clinical studyinvolvingfactors inherentin the processesofsample
preparationandimaging.Examplesincludevariabilityinvolumeof
serum used, amount of fluorophore added, intensity of the light
source, and factors influencing the fluorescence intensity of the
subclasses. How much of the 5% overall error is due to these
factors? To estimate this effect, we normalized the fluorescence
intensitiesof eachof thesubclasses to thesum of theintensitiesof
eachofthesubclasses.For example,the integrated intensity of the
LDL-4 subclass is 42500 (Figure 6). This intensity represents
17.4% of the total intensity of the profile. The distribution is
identical in form, as expected, but the overall precision as been
improved from 4.42% to 3.69%, a small, but significant improve-
ment. Whether classification is influenced using the original data
(Mode 1) or the normalized data (Mode 2) is a question that will
be addressed in the application to clinical studies.
’CONCLUSIONS
Wehaveshownheremethodstoreducetheerrorinlipoprotein
proﬁling through understanding the mechanics of the density
gradientandﬂuorescentimaginginordertousethistechniqueasa
toolforclinicalstudiesinmedicalresearch.Enhancedspinvolume
allows for better separation of the lipoprotein proﬁles. Changing
the layering medium reduces inherent errors present in the
lipoproteindensityproﬁle.Furthermore,aproposednewsystema-
ticformofdataanalysis,Mode2,showspotentialforapplicationto
clinicalstudies.Asaresultoftheseandothertechniquesdescribed
in this study, a high precision method for the measurement of
lipoprotein proﬁles (HPLDP) has been produced for application
toclinical studies. Thismethodiscurrentlybeingused in ongoing
clinical studies in our laboratory. Consequently, this report also
serves as a detailed reference for how the lipoprotein density
proﬁle is measured for these clinical studies.
Finally, we have made a concerted eﬀort to address the long-
standing general belief that lipoproteins are unstable when
exposed to the forces of ultracentrifugation. If sedimentation
were the only force, that would be the case, but sedimentation
equilibrium provides a balance of sedimentation and diﬀusion
that is so gentle that it takes 6 h for the lipoprotein particle to
move a few millimeters. Further, the ionic strength of the
NaBiEDTA is close to physiological levels which will allow for
the measurement of lipoproteins as close to their natural state as
possible. Coupled with the shorter spin time compared to the
gold standard (6 h vs 48 h) and reduced temperature (278 K vs
room temperature), we are conﬁdent that lipoprotein density
proﬁle measured by this method has the precision to determine
whether it can be used to obtain a more accurate classiﬁcation of
subjects at risk for CVD. This feature is the overall objective for
the development of this method. Other factors besides density
could be contributing to the classiﬁcation. Subject variability in
the uptake and ﬂuorescence of the NBD ceramide as well as the
stability of the lipoproteins under DGU conditions may actually
contribute to the distinction between subjects and will therefore
aid in the classiﬁcation of risk.
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